<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03195374</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-338</org_study_id>
    <secondary_id>2016-A00648-43</secondary_id>
    <nct_id>NCT03195374</nct_id>
  </id_info>
  <brief_title>Prescription Opioid Misuse Assessment</brief_title>
  <acronym>POMA 4</acronym>
  <official_title>Assessment of the Prevalence of Analgesics Opioid Misuse in Chronic Non-cancer Pain Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CEIP-A Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CEIP-A Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CEIP-A Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CEIP-A Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CEIP-A Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CEIP-A Nantes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CEIP-A Poitiers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CEIP-A Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CEIP-A Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic pain is a worldwide health problem due to its high prevalence and its difficult
      management with a significant impact on quality of life. Pain and addiction co-occur
      frequently. Indeed, the prevalence of addiction in patients with chronic non-cancer pain may
      affect from 0% to 50% of patients (Højsted et al 2010). This large variability in the
      estimation of addiction prevalence in chronic non-cancer pain patients is at least partly due
      to a lack of standardization of the selected patients from the clinical or therapeutic point
      of view and the lack of consensus in the use of a specific evaluation tool or gold standard.
      Indeed, several tools are currently available at the international level with varying
      efficiencies and precisions (Chou et al 2009, Turk, Swanson, and Gatchel 2008, Højsted and
      Sjøgren 2007). In France, no data are available on the prevalence of analgesic opioid misuse
      in chronic non-cancer pain patients, due to the lack clinical studies and validated tools in
      French.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study . Each addictovigilance centre will contact Pain Clinics in
      order to enroll patients meeting the inclusion criteria. The questionnaires will be prepared
      and sent to the participating centres by the coordinating centre (Clermont-Ferrand).
      Participation in the study will be systematically proposed by the physician during the study
      inclusion period (3 months). Patients meeting all inclusion criteria will be enrolled after
      receiving oral information about the study.

      This questionnaire can be semi-directed (doctor / nurse / CRA) and will be carried out during
      a consultation as part of their usual care. Answering the questionnaire should take no more
      than 10 minutes. No additional diagnostic or monitoring procedures will be applied to
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale</measure>
    <time_frame>at day 1</time_frame>
    <description>A score ≥ 2 is considered positive and will define a misuse behavior</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic opioids used by the patient will be collected in the questionnaire</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' profiles and associated risk factors of opioid misuse will be described through socio-demographic contained in the questionnaire</measure>
    <time_frame>at day 1</time_frame>
    <description>age, gender, family situation, employment status) and clinical data (type of pain, age of painful pathology, psychiatric comorbidities, abuse of other substances, etc</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1068</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Patients with chronic non-cancer pain</arm_group_label>
    <description>Each addictovigilance centre will contact Pain Clinics in order to enroll patients meeting the inclusion criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prescription Opioid Misus Index</intervention_name>
    <description>Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale. A score ≥ 2 is considered positive and will define a misuse behavior.</description>
    <arm_group_label>Patients with chronic non-cancer pain</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Each addictovigilance centre will contact Pain Clinics in order to enroll patients meeting
        the inclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (male or female) ≥ 18 years old

          -  Patients with chronic non-cancer pain for at least 6 months

          -  Patients treated with analgesic opioids for at least 3 months

        Exclusion Criteria:

          -  Patients (male or female) &lt; 18 years old

          -  Patients with chronic pain for less than 6 months

          -  Patients with cancer pain

          -  Patients treated with analgesic opioids for less than 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas AUTHIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne</state>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas AUTHIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Analgesic opioids</keyword>
  <keyword>Misuse</keyword>
  <keyword>Use disorder</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

